$22.05
0.64% today
Nasdaq, Sep 04, 09:43 pm CET
ISIN
NL00150005Y4
Symbol
PHVS

Pharvaris NV Stock price

$21.91
+0.68 3.18% 1M
+6.59 43.02% 6M
+2.74 14.29% YTD
+4.36 24.84% 1Y
+12.51 133.09% 3Y
+1.91 9.55% 5Y
+1.91 9.55% 10Y
+1.91 9.55% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.59 2.62%
ISIN
NL00150005Y4
Symbol
PHVS
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.2b
Net debt
positive
Cash
$232.7m
Shares outstanding
54.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.5
Financial Health
Equity Ratio
91.9%
Return on Equity
-50.1%
ROCE
-89.6%
ROIC
-3,488.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-192.7m | $-204.5m
EBIT
$-193.0m | $-201.2m
Net Income
$-196.2m | $-188.3m
Free Cash Flow
$-160.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-42.7% | -20.6%
EBIT
-42.6% | -18.4%
Net Income
-47.5% | -20.3%
Free Cash Flow
-38.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.6
FCF per Share
$-2.9
Short interest
0.8%
Employees
114
Rev per Employee
$0.0
Show more

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

15x Buy
88%
1x Hold
6%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

Buy
88%
Hold
6%
Sell
6%

Financial data from Pharvaris NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
29% 29%
-
- Research and Development Expense 137 137
49% 49%
-
-193 -193
43% 43%
-
- Depreciation and Amortization 0.40 0.40
29% 29%
-
EBIT (Operating Income) EBIT -193 -193
43% 43%
-
Net Profit -196 -196
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Neutral
Seeking Alpha
about 11 hours ago
Pharvaris N.V. (NASDAQ:PHVS ) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Wim Souverijns - Chief Commercial Officer Peng Lu - Chief Medical Officer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Okay.
Neutral
GlobeNewsWire
23 days ago
Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026 Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of...
Positive
Seeking Alpha
about one month ago
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline data in Q4 2025 for on-demand HAE and CHAPTER-3 prophylaxis data expected in the second half of 2026. Deucrictibant's unique oral formulation and dual-use potential could capture significant market...
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Berndt Modig
Employees 114
Founded 2015
Website pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today